Literature DB >> 28865890

Natriuretic Propeptides as Markers of Atrial Fibrillation Burden and Recurrence (from the AMIO-CAT Trial).

Stine Darkner1, Jens Peter Goetze2, Xu Chen3, Kristoffer Henningsen3, Steen Pehrson3, Jesper Hastrup Svendsen4.   

Abstract

Natriuretic peptides are established plasma markers of systolic heart failure, but their usefulness for the evaluation of atrial fibrillation (AF) is unknown. We examined mid-regional pro-atrial natriuretic peptide (MR-proANP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients undergoing ablation for AF. A subpopulation of 102 patients (median age 60 [52;65], 82% male) from the AMIO-CAT trial (Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study) undergoing ablation for paroxysmal (n = 55) or persistent (n = 47) AF was studied. MR-proANP and NT-proBNP were measured before ablation and at 1, 3, and 6 months' follow-up. Three-day Holter monitoring was performed before ablation, and 6 to 8 weeks and 6 months after ablation. Plasma MR-proANP and NT-proBNP concentrations were higher during AF than during sinus rhythm before ablation (188 pmol/L [131;260] vs 94 pmol/L [64;125], p <0.001; 78 pmol/L [43;121] vs 10.3 pmol/L [5.9;121], p <0.001) and at 1, 3, and 6 months' follow-up. Categories of AF burden on 3-day Holter monitoring (0%, 0% to 99%, and 99% to 100%) were associated with plasma concentrations of both MR-proANP (94 pmol/L [55;127] vs 117 pmol/L [88;185] vs 192 pmol/L [127;261], p <0.001) and NT-proBNP (10 pmol/L [5.9;22] vs 22 pmol/L [8.9;53] vs 81 pmol/L [45;116], p <0.001). In a multivariate regression analysis, however, there was no significant association between baseline propeptide concentrations and recurrence of AF at 6 months' follow-up. In conclusion, AF was associated with higher plasma concentrations of MR-proANP and NT-proBNP than sinus rhythm. Moreover, AF burden was associated with subsequent concentrations of both MR-proANP and NT-proBNP. The results suggest that natriuretic propeptide measurement reflects functional cardiac dysfunction during AF, and that AF burden should be included in biochemical assessment of left ventricular dysfunction.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28865890     DOI: 10.1016/j.amjcard.2017.07.018

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

2.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

Review 3.  Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation.

Authors:  Masako Baba; Kentaro Yoshida; Masaki Ieda
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

4.  Influencing factors of NT-proBNP level inheart failure patients with different cardiacfunctions and correlation with prognosis.

Authors:  Liang Xu; Yanchun Chen; Yanni Ji; Song Yang
Journal:  Exp Ther Med       Date:  2018-05-02       Impact factor: 2.447

Review 5.  Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation.

Authors:  Stephan Willems; Christian Meyer; Joseph de Bono; Axel Brandes; Lars Eckardt; Arif Elvan; Isabelle van Gelder; Andreas Goette; Michele Gulizia; Laurent Haegeli; Hein Heidbuchel; Karl Georg Haeusler; Josef Kautzner; Lluis Mont; G Andre Ng; Lukasz Szumowski; Sakis Themistoclakis; Karl Wegscheider; Paulus Kirchhof
Journal:  Eur Heart J       Date:  2019-12-07       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.